Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naive Chronic Hepatitis B Patients in Korea.

ABSTRACT:

Background

The occurrence of hepatocellular carcinoma (HCC) is a major concern during antiviral therapy for chronic hepatitis B. There are conflicting opinions regarding the effects of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) on HCC prevention. We assessed these two antiviral medications for preventing HCC in treatment-naïve patients with chronic hepatitis B.

Methods

We conducted a retrospective cohort study using nationwide claims data from the Korea Health Insurance Review and Assessment Service. We included 55,473 treatment-naïve adult cases where ETV or TDF treatment was started between 2013 and 2017 (cohort 1). The ETV and TDF groups were matched 1:2 based on age, sex, comorbidities, hospital type, and index date year. Patients were followed up until Dece

SUBMITTER: Choi H 

PROVIDER: S-EPMC8042481 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature